Trials / Completed
CompletedNCT04369248
Hepassocin Levels in Patients With Polycystic Ovary Syndrome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (actual)
- Sponsor
- Fatma ketenci gencer · Other Government
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.
Detailed description
Hepassocin, also known as Fibrinogen-like-protein or hepatocyte-derived fibrinogen-related protein 1, is a new marker for obesity and insulin resistance. In hepatic injury, it protects liver cells and promotes regeneration. High levels of hepassocin was shown to be independently associated with HOMA-IR and diabetes. Since insulin resistance is known to be seen in patients with PCOS, it may be expected that hepassocin levels may be higher in this group of patients.
Conditions
- Hepassocin (Hepatocyte-derived Fibrinogen-related Protein 1)
- Polycystic Ovary Syndrome
- Obesity
- Insulin Resistance
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | hepassocin | hepassocin levels in polycystic ovary syndrome |
Timeline
- Start date
- 2020-01-03
- Primary completion
- 2020-03-15
- Completion
- 2020-03-25
- First posted
- 2020-04-30
- Last updated
- 2020-04-30
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04369248. Inclusion in this directory is not an endorsement.